FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136388199> ?p ?o ?g. }

• W3136388199 endingPage "3628" @default.
• W3136388199 startingPage "3616" @default.
• W3136388199 abstract "Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind, placebo-controlled TOURMALINE-MM2 trial, transplant-ineligible NDMM patients were randomized to ixazomib 4 mg (n = 351) or placebo (n = 354) plus Rd. After 18 cycles, dexamethasone was discontinued and treatment was continued using reduced-dose ixazomib (3 mg) and lenalidomide (10 mg) until progression/toxicity. The primary endpoint was progression-free survival (PFS). Median PFS was 35.3 vs 21.8 months with ixazomib-Rd vs placebo-Rd, respectively (hazard ratio [HR], 0.830; 95% confidence interval, 0.676-1.018; P = .073; median follow-up, 53.3 and 55.8 months). Complete (26% vs 14%; odds ratio [OR], 2.10; P < .001) and ≥ very good partial response (63% vs 48%; OR, 1.87; P < .001) rates were higher with ixazomib-Rd vs placebo-Rd. In a prespecified high-risk cytogenetics subgroup, median PFS was 23.8 vs 18.0 months (HR, 0.690; P = .019). Overall, treatment-emergent adverse events (TEAEs) were mostly grade 1/2. With ixazomib-Rd vs placebo-Rd, 88% vs 81% of patients experienced grade ≥3 TEAEs, 66% vs 62% serious TEAEs, and 35% vs 27% TEAEs resulting in regimen discontinuation; 8% vs 6% died on study. Addition of ixazomib to Rd was tolerable with no new safety signals and led to a clinically meaningful PFS benefit of 13.5 months. Ixazomib-Rd is a feasible option for certain patients who can benefit from an all-oral triplet combination. This trial was registered at www.clinicaltrials.gov as #NCT01850524." @default.
• W3136388199 created "2021-03-29" @default.
• W3136388199 creator A5001851529 @default.
• W3136388199 creator A5006671522 @default.
• W3136388199 creator A5011687418 @default.
• W3136388199 creator A5013980586 @default.
• W3136388199 creator A5014431889 @default.
• W3136388199 creator A5018685925 @default.
• W3136388199 creator A5023276777 @default.
• W3136388199 creator A5026574827 @default.
• W3136388199 creator A5040545724 @default.
• W3136388199 creator A5042776012 @default.
• W3136388199 creator A5043351209 @default.
• W3136388199 creator A5043526996 @default.
• W3136388199 creator A5044238802 @default.
• W3136388199 creator A5054416214 @default.
• W3136388199 creator A5055854701 @default.
• W3136388199 creator A5065238694 @default.
• W3136388199 creator A5066940168 @default.
• W3136388199 creator A5069449708 @default.
• W3136388199 creator A5070014603 @default.
• W3136388199 creator A5071589084 @default.
• W3136388199 creator A5073842707 @default.
• W3136388199 creator A5083431639 @default.
• W3136388199 date "2021-03-24" @default.
• W3136388199 modified "2023-10-10" @default.
• W3136388199 title "Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma" @default.
• W3136388199 cites W1608379611 @default.
• W3136388199 cites W1929906157 @default.
• W3136388199 cites W1994402477 @default.
• W3136388199 cites W2003734726 @default.
• W3136388199 cites W2048483323 @default.
• W3136388199 cites W2059707463 @default.
• W3136388199 cites W2096207943 @default.
• W3136388199 cites W2107384529 @default.
• W3136388199 cites W2141105112 @default.
• W3136388199 cites W2159771593 @default.
• W3136388199 cites W2162771614 @default.
• W3136388199 cites W2191867422 @default.
• W3136388199 cites W2299833483 @default.
• W3136388199 cites W2318069817 @default.
• W3136388199 cites W2343386476 @default.
• W3136388199 cites W2439611081 @default.
• W3136388199 cites W2465273882 @default.
• W3136388199 cites W2567188480 @default.
• W3136388199 cites W2571509750 @default.
• W3136388199 cites W2592320020 @default.
• W3136388199 cites W2614011808 @default.
• W3136388199 cites W2752598794 @default.
• W3136388199 cites W2766948867 @default.
• W3136388199 cites W2769593282 @default.
• W3136388199 cites W2772566228 @default.
• W3136388199 cites W2783965560 @default.
• W3136388199 cites W2790656729 @default.
• W3136388199 cites W2801322837 @default.
• W3136388199 cites W2811240708 @default.
• W3136388199 cites W2899675310 @default.
• W3136388199 cites W2900691306 @default.
• W3136388199 cites W2904778784 @default.
• W3136388199 cites W2912018514 @default.
• W3136388199 cites W2924950986 @default.
• W3136388199 cites W2936045790 @default.
• W3136388199 cites W2947874495 @default.
• W3136388199 cites W2949893945 @default.
• W3136388199 cites W2977656232 @default.
• W3136388199 cites W2979948334 @default.
• W3136388199 cites W3006419152 @default.
• W3136388199 cites W3012199294 @default.
• W3136388199 cites W3015023972 @default.
• W3136388199 cites W3022981424 @default.
• W3136388199 cites W3033878955 @default.
• W3136388199 doi "https://doi.org/10.1182/blood.2020008787" @default.
• W3136388199 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8462404" @default.
• W3136388199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33763699" @default.
• W3136388199 hasPublicationYear "2021" @default.
• W3136388199 type Work @default.
• W3136388199 sameAs 3136388199 @default.
• W3136388199 citedByCount "41" @default.
• W3136388199 countsByYear W31363881992021 @default.
• W3136388199 countsByYear W31363881992022 @default.
• W3136388199 countsByYear W31363881992023 @default.
• W3136388199 crossrefType "journal-article" @default.
• W3136388199 hasAuthorship W3136388199A5001851529 @default.
• W3136388199 hasAuthorship W3136388199A5006671522 @default.
• W3136388199 hasAuthorship W3136388199A5011687418 @default.
• W3136388199 hasAuthorship W3136388199A5013980586 @default.
• W3136388199 hasAuthorship W3136388199A5014431889 @default.
• W3136388199 hasAuthorship W3136388199A5018685925 @default.
• W3136388199 hasAuthorship W3136388199A5023276777 @default.
• W3136388199 hasAuthorship W3136388199A5026574827 @default.
• W3136388199 hasAuthorship W3136388199A5040545724 @default.
• W3136388199 hasAuthorship W3136388199A5042776012 @default.
• W3136388199 hasAuthorship W3136388199A5043351209 @default.
• W3136388199 hasAuthorship W3136388199A5043526996 @default.
• W3136388199 hasAuthorship W3136388199A5044238802 @default.
• W3136388199 hasAuthorship W3136388199A5054416214 @default.
• W3136388199 hasAuthorship W3136388199A5055854701 @default.
• W3136388199 hasAuthorship W3136388199A5065238694 @default.

• next